Search

everythinglearnresearchcommunity

for

Search:↓

New methods to improve the healing abilities of mesenchymal stem cells for disease treatment are promising but need more research.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Loss of OGG1 increases skin inflammation and auto-antibodies in lupus.

CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.

Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Dysplastic nevi have unique gene expressions, making them distinct from common melanocytic nevi.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A woman's hair loss during treatment with specific hepatitis C drugs grew back after stopping the medication.

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Alopecia Areata might be linked to Crohn's disease.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.

Somatostatin may help protect hair follicles from immune attacks.

TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.

Apremilast did not work for treating severe alopecia areata.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

Zinc supplementation may help improve treatment outcomes for chronic hepatitis C.

T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.

Abrocitinib may effectively treat stubborn alopecia universalis.

Mesenchymal stem cells in people with Hidradenitis Suppurativa are more inflammatory, possibly contributing to the disease.

Hepatitis B virus exposure may be linked to increased risk of alopecia areata.

Mechlorethamine treatment regrew hair in mice by killing immune cells causing hair loss without harming hair follicles.

ILC1-like cells can independently cause alopecia areata.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Old treatments for other skin conditions showed promise for hair regrowth in mice with a hair loss condition.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.